Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6SWP

C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD2 (GSK046)

This is a non-PDB format compatible entry.
Summary for 6SWP
Entry DOI10.2210/pdb6swp/pdb
DescriptorBromodomain-containing protein 2, 1,2-ETHANEDIOL, 4-acetamido-3-fluoranyl-~{N}-(4-oxidanylcyclohexyl)-5-[(1~{S})-1-phenylethoxy]benzamide, ... (4 entities in total)
Functional Keywordsinhibitor, histone, epigenetic reader, bromodomain, brd2, bromodomain containing protein 2, antagonist, transcription
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight13971.07
Authors
Chung, C. (deposition date: 2019-09-22, release date: 2020-04-01, Last modification date: 2024-05-15)
Primary citationGilan, O.,Rioja, I.,Knezevic, K.,Bell, M.J.,Yeung, M.M.,Harker, N.R.,Lam, E.Y.N.,Chung, C.W.,Bamborough, P.,Petretich, M.,Urh, M.,Atkinson, S.J.,Bassil, A.K.,Roberts, E.J.,Vassiliadis, D.,Burr, M.L.,Preston, A.G.S.,Wellaway, C.,Werner, T.,Gray, J.R.,Michon, A.M.,Gobbetti, T.,Kumar, V.,Soden, P.E.,Haynes, A.,Vappiani, J.,Tough, D.F.,Taylor, S.,Dawson, S.J.,Bantscheff, M.,Lindon, M.,Drewes, G.,Demont, E.H.,Daniels, D.L.,Grandi, P.,Prinjha, R.K.,Dawson, M.A.
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Science, 368:387-394, 2020
Cited by
PubMed Abstract: The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions. To explore the individual functional contributions of the first (BD1) and second (BD2) bromodomains in biology and therapy, we developed selective BD1 and BD2 inhibitors. We found that steady-state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins. BD1 inhibitors phenocopied the effects of pan-BET inhibitors in cancer models, whereas BD2 inhibitors were predominantly effective in models of inflammatory and autoimmune disease. These insights into the differential requirement of BD1 and BD2 for the maintenance and induction of gene expression may guide future BET-targeted therapies.
PubMed: 32193360
DOI: 10.1126/science.aaz8455
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.604 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon